Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHA:603139)
38.93
-0.07 (-0.18%)
Sep 10, 2026, 2:45 PM CST
SHA:603139 Revenue
Shaanxi Kanghui Pharmaceutical had revenue of 111.97M CNY in the quarter ending June 30, 2026, a decrease of -11.26%. This brings the company's revenue in the last twelve months to 429.09M, down -21.05% year-over-year. In the year 2025, Shaanxi Kanghui Pharmaceutical had annual revenue of 471.29M, down -16.09%.
Revenue (ttm)
429.09M
Revenue Growth
-21.05%
P/S Ratio
9.08
Revenue / Employee
533.69K
Employees
804
Market Cap
3.90B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 471.29M | -90.35M | -16.09% |
| Dec 31, 2024 | 561.63M | -111.33M | -16.54% |
| Dec 31, 2023 | 672.96M | 181.45M | 36.92% |
| Dec 31, 2022 | 491.51M | 48.75M | 11.01% |
| Dec 31, 2021 | 442.76M | 28.69M | 6.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Starry Pharmaceutical | 2.46B |
| Zhuhai Rundu Pharmaceutical | 1.34B |
| Tibet Weixinkang Medicine | 1.13B |
| Harbin Medisan Pharmaceutical | 805.09M |
| Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD | 737.90M |
| Nanjing Hicin Pharmaceutical | 726.62M |
| Newland Pharmaceutical | 710.55M |
| Shanghai Xiao Fang Pharmaceutical | 537.42M |